{"schema_version":"1.0","type":"article","title":"阿茲海默症20年來的假說開始崩盤？","url":"https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse.md","lang":"zh-Hant","date":"2026-05-01","publish_at":"2026-05-01T10:30:00+08:00","updated_at":"2026-05-01","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","Alzheimer","amyloid","FDA"],"summary":"【阿茲海默症的 Aβ 信仰，真的開始崩了嗎？】📌 4 月 16 日，一篇來自 Cochrane 的系統性綜述，再次把阿茲海默症領域最核心、也最具爭議的主軸，推回風暴中心。這份綜述的訊息極其刺耳：對輕度","key_points":[],"facts":[],"sections":["01｜為什麼這份報告像一份「宣判書」？","02｜但這不是故事的全部：為什麼藥廠、臨床醫師與病患團體立刻反擊？","03｜其實，Aβ 路線的信任危機，早就不是今天才開始","04｜真正的分水嶺，其實寫在監管端：FDA 與歐洲看的是同一份資料，卻做出不同判斷","05｜所以，Aβ 假說該被放棄嗎？"],"references":[{"title":"[0]:公開資料＆各公司官網","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Are medicines (anti-amyloid monoclonal antibodies) that reduce the build-up of abnormal proteins in the brain an effective treatment for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease, and do they cause unwanted effects?","source":"","date":"","url":""},{"title":"https://www.cochrane.org/evidence/CD016297_are-medicines-anti-amyloid-monoclonal-antibodies-reduce-build-abnormal-proteins-brain-effective","source":"","date":"","url":"https://www.cochrane.org/evidence/CD016297_are-medicines-anti-amyloid-monoclonal-antibodies-reduce-build-abnormal-proteins-brain-effective"},{"title":"www.cochrane.org","source":"","date":"","url":""},{"title":"\"Are medicines (anti-amyloid monoclonal antibodies) that reduce the build-up of abnormal proteins in the brain an effective treatment for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease, and do they cause unwanted effects?","source":"Cochrane\"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Explaining the amyloid research study controversy","source":"Alzheimer's Society","date":"","url":""},{"title":"Allegations have been made about a research study investigating amyloid protein build up in the brains of people living with Alzheimer’s disease. Here we explore and explain the controversy.","source":"","date":"","url":""},{"title":"www.alzheimers.org.uk","source":"","date":"","url":""},{"title":"\"Explaining the amyloid research study controversy","source":"Alzheimer's Society\"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"Leaders in the dementia field react to a report with ‘major limitations’ labelling Alzheimer’s drugs as ineffective - Alzheimer's Research UK","source":"","date":"","url":""},{"title":"A new report suggests that anti-amyloid drugs are ineffective at slowing dementia symptoms. Read more to find out what the research shows.","source":"","date":"","url":""},{"title":"www.alzheimersresearchuk.org","source":"","date":"","url":""},{"title":"\"Leaders in the dementia field react to a report with ‘major limitations’ labelling Alzheimer’s drugs as ineffective - Alzheimer's Research UK\"","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at AAIC 2024","source":"News ReleaseNews Release：2024","date":"","url":""},{"title":"Eisai's news release New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at AAIC 2024 is posted.","source":"","date":"","url":""},{"title":"www.eisai.com","source":"","date":"","url":""},{"title":"\"New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at AAIC 2024","source":"News ReleaseNews Release：2024","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"Trial of Donanemab in Early Symptomatic Alzheimer Disease","source":"","date":"","url":""},{"title":"This randomized clinical trial examines the efficacy and adverse effects of donanemab, a monoclonal antibody designed to clear brain amyloid plaque, among patients with early symptomatic Alzheimer disease.","source":"","date":"","url":""},{"title":"jamanetwork.com","source":"","date":"","url":""},{"title":"\"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","source":"Trials","date":"","url":""}],"images":[{"alt":"Dcard 原圖：阿茲海默症20年來的假說開始崩盤？","url":"https://drugnews.com.tw/assets/articles/alzheimers-amyloid-hypothesis-collapse/dcard-01.webp"},{"alt":"Dcard 原圖：阿茲海默症20年來的假說開始崩盤？","url":"https://drugnews.com.tw/assets/articles/alzheimers-amyloid-hypothesis-collapse/dcard-02.webp"},{"alt":"Dcard 原圖：阿茲海默症20年來的假說開始崩盤？","url":"https://drugnews.com.tw/assets/articles/alzheimers-amyloid-hypothesis-collapse/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/alzheimers-amyloid-hypothesis-collapse/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-01）。阿茲海默症20年來的假說開始崩盤？。https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-01-alzheimers-amyloid-hypothesis-collapse-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}